Home
overview
“Congratulations on a great meeting. Excellent learning opportunities and fun networking”
Dr Herbert Fritsche, Professor, Laboratory Medicine & Chief, Clinical Chemistry Section, MD Anderson Cancer Centre – Delegate at SMi’s 2007 Biomarker Event
    
SMi’s Biomarkers Summit, the 5th in the biomarkers series offers a unique opportunity to hear about the latest developments from industry leaders. 
      
Examine the latest developments in the biomarker research, and listen to case studies from the leading companies in the field.
Discussions will include issues on the latest developments in biomarker research from discovery to validation to clinical issues;
  • Biomarkers in early clinical drug development
  • Biomarker validation
  • Protein biomarker discovery
  • Biomarkers as a diagnosis tool
       
Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities.
      
Confirmed speakers include:
  • Mark Fidock, Associate Research Fellow, Head of Biochemical & Molecular Pharmacology, Biomarkers & Translational Biology, Pfizer
  • Ashok Dongre, SRI, Clinical Discovery, Bristol Myers Squibb
  • Dr Michael Tacke, Director, Proteomics, Roche Diagnostics Gmbh
  • Lisa Kyriacou Faulks, Global Biosamples Specialist, Biomarkers & Experimental Medicine, Roche Products
  • Dr Barroso Begona, Associate Director, Bioanalysis, Astellas Pharma International B V
  • Dr Hans Winkler, Senior Director Translational Research, Oncology, Johnson & Johnson
  • Dr Mark Manfredi, Associate Director, Oncology, Millennium Pharmaceuticals
  • Professor William Gallagher, Associate Professor of Cancer Biology, University College Dublin and CEO/CSO OncoMark Ltd
  • Georg Wensing, Head, Pharmacodynamics, Clinical Pharmacology, Bayer
  • Professor Caroline Dive, Head of Clinical & Experimental Pharmacology, Paterson Institue for Cancer Research, University of Manchester
  • Dr Johannes Lampe, Managing Partner, Lampe Konieczny & Company
  • Professor Karol Sikora, Professor, Cancer Medicine, Imperial College, Hammersmith Hospital, London and Scientific Director, Medical Solutions
Chaired by:
Professor William Gallagher, Associate Professor of Cancer Biology, University College Dublin and CEO/CSO OncoMark Ltd
Who Should Attend this Conference?
Vice Presidents,Directors, Heads & Scientists working in the following fields:
  • Biomarkers
  • Screening
  • Genomics
  • Toxicity
  • Imaging
  • Bioinformatics
  • Proteomics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Professor William Gallagher

Professor William Gallagher, Associate Professor Cancer Biology, University College Dublin and CEO/CSO, OncoMark Ltd

9:10 KEYNOTE PRESENTATION

Georg Wensing

Georg Wensing, Head, Pharmacodynamics, Clinical Pharmacology, Bayer*

  • Current and future business models
  • The market shift towards personalised medicine
  • Biomarkers to aid decision making
  • Potential cost savings in drug discovery and development
  • Increasing ROI
  • 9:50 AN INTEGRATED APPROACH TO BIOMARKERS

    Mark Garner

    Mark Garner, Senior Manager, Translational Sciences, Applied Biosystems

  • Biomarker Research is a continuum, going from the untargeted discovery of potential candidate markers in phenotypically characterized samples to their targeted verification in larger sample sets
  • Although different experimental techniques are used at different stages of research, data and information flow back and forth to inform the experimental design
  • Sequence-based information can be used as a bridge across different "omic" technologies
  • The tools and workflows to accomplish this type of integrated approach to biomarkers will be described
  • 10:30 Morning Coffee

    11:00 LOST IN TRANSLATION

    Mark Fidock

    Mark Fidock, Associate Research Fellow, Biomarkers & Translational Biology, Pfizer

  • An industry-wide problem is that a significant number of new chemical entities (NCEs) fail in clinical studies due to a lack of efficacy and we don't always understand why
  • This presentation will discuss possible reasons behind this issue
  • It will Illustrate the need to have validated Proof-of-Pharmacology (POP) Biomarkers for each target mechanism
  • These POP Biomarkers will facilitate better translation from pre-clinical to clinical development and  provide key learning's for each target mechanism
  • 11:40 FROM BIOMARKERS TO PERSONALISED MEDICINE FOR CANCER

    Karol Sikora

    Karol Sikora, Non Executive, Medical Solutions Plc

  • Molecularly targeted drugs are now becoming commonplace in cancer care
  • Getting the right drug to the right patient will rely on novel diagnostic strategies
  • Molecular pathology has not seen the massive investment of drug discovery
  • Increasing cost effectiveness of high cost drugs will be essential
  • The shift to molecular diagnostics for cancer will change prescription habits over the next
  • 12:20 Networking Lunch

    13:40 AN “ACUTE KIDNEY INJURY TEST™” FROM PRECLINICAL STUDIES TO CLINICAL APPLICATIONS

    Martin Shaw

    Martin Shaw, Senior Scientific Officer, Biotrin International

  • A new biomarker discovery technology “Histomics®”
  • Development of multiplex tests
  • Validation of Preclinical data
  • The challenges in gaining clinical acceptance
  • 14:20 APOPTOSIS BIOMARKERS

    Frank Neumann

    Frank Neumann, Proprietor, Bioaxxess Technology Consulting

  • Successful translation of a scientific discovery into a validated CE-marked biomarker assay
  • "M30-Apoptosense ELISA®” in preclinical and early clinical drug development
  • Evaluation as a diagnosis tool for liver injury and treatment response marker
  • LowCross-Buffer®” for immuno-assay optimization for biomarkers in interference-rich blood samples
  • 15:00 TEST PATIENT RESPONSE AND DIRECT KINASE INHIBITOR EFFECTS: KINASE ACTIVITY PROFILING IN TUMOR HOMOGENATES

    Rob Ruijtenbeek

    Rob Ruijtenbeek , Vice President, R & D, PamGene International

  • Activity Based Biomarkers using Multiplex Peptide Micro-arrays
  • Oncology Case Studies: Clinical, Translational and Preclinical Use
  • Next Step: Perfect Fit to Routine Diagnostics Workflow
  • 15:40 Afternoon Tea

    16:10 FILLING DIAGNOSTIC GAPS

    Dr Michael Tacke

    Dr Michael Tacke, Director, Proteomics, Roche Diagnostics Gmbh

  • Early detection of cancer
  • Proteomics technologies for discovery of novel markers
  • Validation strategies for marker candidates
  • Clinical validation of novel markers
  • 16:50 TISSUE MICROARRAY TECHNOLOGY: APPLICATION TO CANCER AND TOXICOLOGICAL BIOMARKER DEVELOPMENT

    Professor William Gallagher

    Professor William Gallagher, Associate Professor Cancer Biology, University College Dublin and CEO/CSO, OncoMark Ltd

  • Tissue microarrays as translational research tools
  • Bridging from omic discovery to validation
  • Manual and automated image analysis
  • Case studies in cancer and toxicology
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    Professor William Gallagher

    Professor William Gallagher, Associate Professor Cancer Biology, University College Dublin and CEO/CSO, OncoMark Ltd

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Professor William Gallagher

    Professor William Gallagher, Associate Professor Cancer Biology, University College Dublin and CEO/CSO, OncoMark Ltd

    9:10 ETHICAL AND LOGISTICAL ASPECTS OF BIOMARKER SAMPLING

    Lisa Kyriacou Faulks

    Lisa Kyriacou Faulks, Global Biosamples Specialist, Biomarkers & Experimental Medicine, Roche Products

  • Ethics
  • The worldwide climate on sample banking
  • Challenges with sample collection 
  • Transportation
  • Logistics
  • 9:50 PREDICTING BIOMARKERS USING MODELING, SIMULATION, AND VIRTUAL POPULATIONS

    Ananth Kadambi

    Ananth Kadambi, Senior Scientist, Entelos

  • Rationale
  • Technical Approach
  • Deliverables
  • A biomarker case study
  • 10:30 Morning Coffee

    10:50 BIOMARKERS FOR MECHANISM BASED THERAPIES IN ONCOLOGY, THE ACADEMIC PERSPECTIVE FROM THE LABORATORY-CLINIC INTERFACE

    Professor Caroline Dive

    Professor Caroline Dive, Head of Clinical & Experimental Pharmacology, Paterson Institue for Cancer Research, University of Manchester

  • Early Clinical Trials of Anticancer Drugs
  • Proof of Concept Pharmacodynamic Biomarkers
  • Serological Biomarkers of Cell Death and Angiogenesis
  • Fast track Assay Validation
  • Productive Interaction with the Pharmaceutical Industry
  • 11:30 BIOMARKER VALIDATION

    Dr Barroso Begona

    Dr Barroso Begona, Associate Director, Bioanalysis, Astellas Pharma International B V

  • Biomarkers in clinical drug development
  • Qualification verses validation
  • Challenge for validation of biomarker assays
  • Guidance for biomarker validation
  • 12:10 DISCOVERY AND VALIDATION OF PREDICTIVE RESPONSE MARKERS

    Dr Hans Winkler

    Dr Hans Winkler, Senior Director Translational Research, Oncology, Johnson & Johnson

  • Preclinical Discovery
  • Clinical Discovery
  • Assay Development
  • Clinical Qualification
  • Predictive vs. Prognostic
  • 12:50 Networking Lunch

    14:00 TRANSLATION OF PRECLINICAL MARKERS INTO PHASE I ONCOLOGY STUDIES

    Dr Mark Manfredi

    Dr Mark Manfredi, Associate Director, Oncology, Millennium Pharmaceuticals

  • Aurora A kinase is a key regulator of mitosis
  • Inhibition of Aurora A kinase results in mitotic delay and inhibition of proliferation
  • MLN8054 is an orally active and selective inhibitor of Aurora A kinase.
  • Mechanistic biomarker have been developed to monitor upstream and downstream effects of Aurora A inhibition
  • MLN8054 is currently in phase I clinical development
  • 14:40 ROADMAP FOR IMAGING BIOMARKERS

    Derek Hill

    Derek Hill, CEO, IXICO Ltd

  • Established imaging biomarkers used for regulatory submissions
  • Future opportunities for imaging biomarkers
  • Implementation challenges
  • Where imaging fits in the biomarker landscape
  • 15:20 PROFILING PHARMACEUTICALS FROM A CLINICAL PERSPECTIVE

    Dr Johannes  Lampe

    Dr Johannes Lampe, Managing Partner, Lampe Konieczny & Company

  • Presentation of a concept for the evaluation of biomedical compound and disease characteristics
  • Matching of results may lead to the identification of success factors
  • 16:00 Chairman’s Closing Remarks and Afternoon Tea

    +

    Workshops

    Tissue Microarray & Digital Slide Scanning Technologies in Biomarker Development
    Workshop

    Tissue Microarray & Digital Slide Scanning Technologies in Biomarker Development

    Copthorne Tara Hotel
    6th February 2008
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.